Bank Of New York Mellon Corp Seagen Inc. Transaction History

Bank Of New York Mellon Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $102 Million - $121 Million	867,303 New	867,303 $111 Million
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $5.76 Million - $7.67 Million	42,608 Added 4.41%	1,008,200 $138 Million
Q2 2022 Aug 15, 2022	BUY	$108.81 - $179.33 $2.84 Million - $4.68 Million	26,086 Added 2.78%	965,592 $171 Million
Q1 2022 May 11, 2022	SELL	$119.61 - $157.85 $4.34 Million - $5.73 Million	-36,318 Reduced 3.72%	939,506 $135 Million
Q4 2021 Feb 11, 2022	SELL	$142.57 - $190.86 $4.66 Million - $6.24 Million	-32,713 Reduced 3.24%	975,824 $151 Million
Q3 2021 Nov 12, 2021	BUY	$142.45 - $169.82 $1.69 Million - $2.01 Million	11,865 Added 1.19%	1,008,537 $171 Million
Q2 2021 Aug 11, 2021	SELL	$135.08 - $161.1 $773,738 - $922,780	-5,728 Reduced 0.57%	996,672 $157 Million
Q1 2021 May 13, 2021	SELL	$137.51 - $190.8 $3.17 Million - $4.4 Million	-23,082 Reduced 2.25%	1,002,400 $139 Million
Q4 2020 Feb 16, 2021	BUY	$164.63 - $211.93 $169 Million - $217 Million	1,025,482 New	1,025,482 $180 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.